U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. FDA Bioresearch Monitoring Information
  5. Preface
  1. FDA Bioresearch Monitoring Information

Preface

Public Comment

Comments and suggestions may be submitted at any time to the Division of Compliance Policy (HFC-230), Office of Enforcement, Office of Regulatory Affairs (ORA), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Please refer to the exact title of this document when submitting comments or suggestions. For questions regarding the use or interpretation of this chart contact Chris Anders at (240) 632-6853, or e-mail Christopher.Anders@fda.hhs.gov.

Additional Copies

Additional copies are available from the Internet at: http://www.fda.gov/ora/compliance_ref/bimo/fda_epa_oecd.html. Submit written requests for single copies of the guidance entitled "Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP" to the Division of Compliance Policy (HFC-230), Office of Enforcement, Office of Regulatory Affairs (ORA), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist the office in processing your requests.

Back to Top